MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, RAPP had $196,292K increase in cash & cash equivalents over the period. -$17,599K in free cash flow.

Cash Flow Overview

Change in Cash
$196,292K
Free Cash flow
-$17,599K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-26,925 -50,795
Depreciation and amortization
256 496
Net (accretion) and amortization of investments in marketable securities
-204 528
Non-cash lease expense
567 894
Stock-based compensation expense
4,735 8,429
Prepaid expenses and other current assets
-2,534 5,144
Other assets
362 548
Accounts payable
-179 1,216
Accrued expenses and other current liabilities
1,696 784
Operating lease liabilities
-9 111
Net cash used in operating activities
-17,465 -45,307
Purchases of short-term investments
101,620 56,093
Maturities of short-term investments
44,978 100,033
Purchases of property and equipment
134 313
Net cash used in investing activities
-56,776 43,627
Proceeds from underwritten public offering, net of underwriter discounts and commissions and deferred offering costs
269,834 -
Proceeds from exercise of stock options
636 6
Payment of deferred offering costs
-63
Repurchase of unvested restricted common stock
0 1
Net cash provided by financing activities
270,533 -58
Net (decrease) increase in cash, cash equivalents, and restricted cash
196,292 -1,738
Cash and cash equivalents at beginning of period
56,910 -
Cash and cash equivalents at end of period
251,464 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics, Inc. (RAPP)